After Record Series A, Eutilex Eyes T-Cell, Antibody Partnerships
Executive Summary
Although established only last year, Eutilex is rapidly making its way in the immuno-oncology space. After closing one of the biggest ever Series A funding rounds by a South Korean bioventure, its CEO talks to Scrip about next steps and the priorities for next year.
You may also be interested in...
Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
What's Driving The Uptick In Korea-China Biotech Deals
Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.
Chinese API Maker Huahai Leaps Into IO Via Korean Startup
A frenzy for innovation has more Chinese companies armed with cash shopping for new assets. Huahai is the latest to jump onboard the increasingly competitive immuno-oncology field.